Compare Bristol-Myers Squibb Co (BMY) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Roundhill Magnificent Seven ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Roundhill Magnificent Seven ETF trades at $67.57. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals.
| BMY | MAGS | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $70.94 |
52-Week Low | $42.60 | $55.39 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.99, down 1.02% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights the ETF's strong performance since launch but notes concentration risk and a recent pullback from 2026 highs. The fund provides equal-weight exposure to mega-cap tech stocks, with assets near $4.7 billion as of May 2026.
The outlook for MAGS hinges on the continued growth and AI monetization of its underlying holdings. Key opportunities include potential free cash flow expansion from hyperscalers, but risks involve high expectations, valuation compression, and the cyclical nature of tech leadership. Market sentiment is mixed, balancing long-term growth prospects against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
